<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356798</url>
  </required_header>
  <id_info>
    <org_study_id>PRO-PanFlu-1001</org_study_id>
    <nct_id>NCT00356798</nct_id>
  </id_info>
  <brief_title>Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects</brief_title>
  <official_title>The Phase-I Clinical Trial Protocol for the Pandemic Inactivated Influenza Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Biotech Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology of the PeopleÂ´s Republic of China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <brief_summary>
    <textblock>
      Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical&#xD;
      trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole&#xD;
      virion H5N1 vaccine with aluminium hydroxide adjuvant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date>April 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of pandemic inactivated influenza vaccine by different does.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the immunogenicity of pandemic inactivated influenza vaccine by different does.</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Influenza</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>an inactivated whole virion H5N1 vaccine, adjuvanted</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females, age from 18 to 60 years old;&#xD;
&#xD;
          -  Able to provide proof of identity to the satisfaction of the study clinician&#xD;
             completing the enrollment process;&#xD;
&#xD;
          -  Able and willing to complete the informed consent process.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Woman who is breast-feeding or planning to become pregnant during the following 210&#xD;
             days of study participation;&#xD;
&#xD;
          -  Persons who engage in the following occupations: culturist, slaughter, sale and&#xD;
             forwarder of avian;&#xD;
&#xD;
          -  Subject has a medical history of any of the following: allergic history, or allergic&#xD;
             to any ingredient of vaccine, such as egg, egg protein, etc;&#xD;
&#xD;
          -  Serious adverse reactions to vaccines such as anaphylaxis, hives, respiratory&#xD;
             difficulty, angioedema, or abdominal pain;&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency;&#xD;
&#xD;
          -  Asthma that is unstable or required emergent care, urgent care, hospitalization or&#xD;
             intubation during the past two years or that requires the use of oral or intravenous&#xD;
             corticosteroids;&#xD;
&#xD;
          -  Diabetes mellitus (type I or II), with the exception of gestational diabetes;&#xD;
&#xD;
          -  History of thyroidectomy or thyroid disease that required medication within the past&#xD;
             12 months;&#xD;
&#xD;
          -  Serious angioedema episodes within the previous 3 years or requiring medication in the&#xD;
             previous two years;&#xD;
&#xD;
          -  Bleeding disorder diagnosed by a doctor (e.g. factor deficiency, coagulopathy, or&#xD;
             platelet disorder requiring special precautions) or significant bruising or bleeding&#xD;
             difficulties with IM injections or blood draws;&#xD;
&#xD;
          -  Malignancy that is active or treated malignancy for which there is not reasonable&#xD;
             assurance of sustained cure or malignancy that is likely to recur during the period of&#xD;
             study;&#xD;
&#xD;
          -  Seizure disorder other than 1) febrile seizures under the age of two, 2) seizures&#xD;
             secondary to alcohol withdrawal more than 3 years ago, or 3) a singular seizure not&#xD;
             requiring treatment within the last 3 years;&#xD;
&#xD;
          -  Asplenia, functional asplenia or any condition resulting in the absence or removal o&#xD;
             the spleen;&#xD;
&#xD;
          -  Guillain-Barre Syndrome (GBS);&#xD;
&#xD;
          -  Abnormal result of laboratory test as below:&#xD;
&#xD;
               -  Biochemistry assaying: Alanine Aminotransferase /Serum Glutamate Pyruvate&#xD;
                  Transaminase (ALT), Total Bilirubine Tbil (TBIL), Direct Bilirubine Tbil (DBIL),&#xD;
                  Blood Urea Nitrogen (BUN) and Creatinine (Cr).&#xD;
&#xD;
               -  Routine blood assaying, routine urine assaying.&#xD;
&#xD;
               -  HBsAg positive;&#xD;
&#xD;
          -  Pregnancy test positive for female;&#xD;
&#xD;
          -  Subject has received any of the following substances:&#xD;
&#xD;
               -  Immunosuppressive medications or cytotoxic medications or inhaled corticosteroids&#xD;
                  within the past six months (with the exception of corticosteroid nasal spray for&#xD;
                  allergic rhinitis or topical corticosteroids for an acute uncomplicated&#xD;
                  dermatitis).&#xD;
&#xD;
               -  Blood products within 3 months prior to initial study vaccine administration.&#xD;
&#xD;
               -  Other study drug within 30 days prior to initial study vaccine administration.&#xD;
                  Live attenuated vaccines within 30 days prior to initial study vaccine&#xD;
                  administration.&#xD;
&#xD;
               -  Medically indicated subunit or killed vaccines, e.g. pneumococcal, or allergy&#xD;
                  treatment with antigen injections, within 14 days of study vaccine&#xD;
                  administration.&#xD;
&#xD;
               -  Current anti-TB prophylaxis or therapy.&#xD;
&#xD;
          -  Fever before vaccination, axillary temperature 37.0 centigrades.&#xD;
&#xD;
          -  Psychiatric condition that precludes compliance with the protocol; past or present&#xD;
             psychoses; past or present bipolar disorder requiring therapy that has not been well&#xD;
             controlled on medication for the past two years; disorder requiring lithium; or&#xD;
             suicidal ideation occurring within five years prior to enrollment.&#xD;
&#xD;
          -  Any medical, psychiatric, social condition, occupational reason or other&#xD;
             responsibility that, in the judgment of the investigator, is a contraindication to&#xD;
             protocol participation or impairs a volunteer's ability to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jiangtao Lin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>China-Japan Friendship Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China-Japan Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006 Sep 16;368(9540):991-7.</citation>
    <PMID>16980114</PMID>
  </results_reference>
  <verification_date>November 2007</verification_date>
  <study_first_submitted>July 25, 2006</study_first_submitted>
  <study_first_submitted_qc>July 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <last_update_submitted>November 8, 2007</last_update_submitted>
  <last_update_submitted_qc>November 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2007</last_update_posted>
  <keyword>pandemic</keyword>
  <keyword>influenza</keyword>
  <keyword>H5N1</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

